U.S. Markets close in 5 hrs 28 mins

WuXi AppTec Co., Ltd. (2359.HK)

HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
165.800-5.300 (-3.10%)
At close: 4:08PM HKT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close171.100
Open171.100
Bid165.800 x 0
Ask165.900 x 0
Day's Range164.200 - 173.900
52 Week Range70.214 - 216.000
Volume1,952,814
Avg. Volume2,415,562
Market Cap427.227B
Beta (5Y Monthly)0.87
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.43 (0.24%)
Ex-Dividend DateMay 28, 2021
1y Target EstN/A
  • WuXi AppTec Reports Record First-Quarter 2021 Results
    PR Newswire

    WuXi AppTec Reports Record First-Quarter 2021 Results

    WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its unaudited financial results for the First-Quarter of 2021 ("Reporting Period").

  • PR Newswire

    WuXi AppTec Reports Strong 2020 Annual Results

    WuXi AppTec (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its audited annual results for the year ended December 31, 2020 ("Reporting Period").

  • WuXi AppTec Completes Acquisition of OXGENE to Further Strengthen Cell and Gene Therapy Service Offerings for Global Customers
    PR Newswire

    WuXi AppTec Completes Acquisition of OXGENE to Further Strengthen Cell and Gene Therapy Service Offerings for Global Customers

    WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies. This acquisition enables WuXi AppTec to offer its customers end-to-end support in the creation and development of cutting-edge cell and gene therapies for patients in need worldwide.